Next-Generation Antibody Therapeutics Market with COVID-19 Impact Analysis, By Therapeutic Area, By Technology, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2023-2030
보고서의 하이라이트
차세대 항체 치료제 시장 규모는 2022년 50억 710만 달러로 평가되었고, 2023년부터 2030년까지 연평균 복합 성장률(CAGR) 10.3%로 확대될 것으로 예상됩니다.
차세대 항체 치료제 시장 - 시장 역학
류마티스 관절염, 염증성 장질환, 크론병, 암 등 다양한 만성질환의 유병률 증가로 시장 수요 촉진
차세대 항체 치료는 만성질환 치료에 큰 잠재력을 가지고 있습니다. 최근 심혈관 질환, 당뇨병, 암, 자가면역 질환, 신경 퇴행성 질환, 호흡기 질환 등 여러 만성 질환의 유병률이 증가하고 있습니다. 세계보건기구(WHO)에 따르면, 심혈관질환(CVDs)은 세계 사망 원인 1위로 매년 1,790만 명의 목숨을 앗아가는 것으로 추정됩니다. 그러나 만성질환의 전통적인 치료법에는 화학요법, 방사선 치료, 면역억제제, 증상을 억제하는 약물의 장기적인 사용 등이 있습니다. 생명공학 분야의 지속적인 발전과 질병 메커니즘에 대한 이해가 깊어짐에 따라 차세대 항체 치료는 다양한 만성 질환의 치료 상황에 혁명을 일으켜 환자의 치료 성과와 삶의 질을 향상시킬 수 있는 잠재력을 가지고 있습니다.
차세대 항체 치료제 시장 - 주요 인사이트
- 차세대 항체 치료제 산업은 지속 가능한 성장에 대한 인식이 높아짐에 따라 높은 성장률로 성장할 것으로 예상됩니다.
- 치료 분야 세분화에 따라 2022년에는 암 분야가 가장 높은 시장 점유율을 차지했습니다.
- 기술 부문별로는 항체 약물 복합체가 2022년 주요 유형이었습니다.
- 지역별로는 북미가 2022년 매출을 주도했습니다.
차세대 항체 치료제 시장 - 세분화 분석 :
차세대 항체 치료 세계 시장은 치료 분야, 기술, 지역에 따라 구분됩니다.
시장은 치료 영역에 따라 암 영역과 자가면역 및 염증 영역의 세 가지 범주로 나뉩니다. 종양학은 시장을 독점하고 있으며, 예측 기간 동안에도 그 우위를 유지할 것으로 보입니다. 암 분야는 차세대 항체 치료가 큰 진전을 이루며 큰 잠재력을 보여준 주요 치료 분야 중 하나입니다.
시장은 기술별로 항체 약물 복합체(ADC), 이중 특이성 항체, Fc 변형 항체, 항체 단편 및 항체 유사 단백질, 바이오시밀러 항체 제품 등 3가지 범주로 나뉩니다. 항체-약물 복합체는 차세대 항체 치료제 시장을 독점하고 있습니다. 항체 약물 복합체(ADC)는 단클론 항체의 특이성과 화학요법제의 세포독성 작용을 동시에 가진 차세대 항체 치료제의 일종입니다.
차세대 항체 치료제 시장 - 지리적 통찰
지역적으로 이 시장은 북미, 라틴아메리카, 유럽, 아시아태평양, 중동 및 아프리카로 나뉩니다. 이 지역들은 사업 운영 국가에 따라 더 세분화됩니다. 북미는 자가 면역 질환 증가와 의료 지출 증가로 인해 차세대 항체 치료제 시장의 성장을 주도할 것으로 예상됩니다. 차세대 항체 치료는 표적화된 특정 중재를 제공함으로써 자가면역질환 치료에 큰 잠재력을 보여주고 있습니다. 미국 국립보건원에 따르면, 최대 2,350만 명의 미국인이 자가면역질환을 앓고 있으며, 그 유병률이 증가하고 있습니다. 차세대 항체 치료는 이러한 과제 중 일부를 해결하고 2021년 의료비 지출이 1,876억 달러로 2020년의 전례 없는 수준보다는 적지만 여전히 팬데믹 이전보다 더 많은 지출을 할 수 있습니다. 정부 주도의 전염병 구호로 인해 기타 연방 정부 프로그램 지출은 2019년 140억 달러에서 2020년 1,931억 달러로 증가했습니다. 미국 의사협회에 따르면 2021년 지출은 719억 달러였습니다. 전반적으로 차세대 항체 치료제 시장은 모든 지역에서 큰 성장 기회가 있을 것으로 예상됩니다.
차세대 항체 치료제 시장 - 경쟁 구도 :
최근 몇 년동안 기존 IgG를 개선한 새로운 항체 치료제가 속속 등장하고 있습니다. 또한, 많은 생명공학 및 제약회사들이 다양한 질환을 대상으로 수백 가지의 차세대 항체 치료제를 임상 개발하고 있습니다. 그러나 아직 많은 과제가 남아있고, 항체 치료제의 잠재력을 완전히 실현하기에는 아직 많은 어려움이 남아 있습니다. 항체 공학 기술이 발전하고 질병 생물학 및 항체의 작용기전이 더 많이 이해됨에 따라 많은 새로운 항체 형식과 항체 유래 분자가 유망한 차세대 치료제로 부상하고 있습니다. 이러한 새로운 항체 포맷과 분자는 약동학 개선, 선택성 향상, 효능 강화와 같은 특수한 특성을 얻기 위해 세심하게 설계 및 엔지니어링되고 있습니다. 많은 기업과 연구기관이 이러한 혁신적인 치료법의 개발과 상용화에 적극적으로 나서고 있습니다. 예를 들어, 2022년 1월 6일, 암젠과 제네레이트 바이오 의약품은 여러 치료 영역과 여러 치료법에 걸쳐 5가지 임상 표적에 대한 단백질 치료제를 발견하고 개발하기 위한 공동 연구 계약을 발표했습니다.
최근 동향
2022년 9월, 단일클론 항체의 진화를 통해 표적 세포를 죽이는 힘 등 특성을 강화하는 엔지니어링을 적용한 차세대 항체 치료제가 탄생했습니다. 여기에는 항체 약물 복합체(ADC), 이중 특이성 항체, 인공 항체, 항체 조각, 나노 바디 등이 포함됩니다.
본 조사의 주요 특징
- 이 보고서는 차세대 항체 치료제 시장 시장 규모, 연평균 성장률(CAGR%), 2022년을 기준연도로 한 추정 및 예측(2023-2030년)을 제공합니다.
- 이 조사 보고서는 고객에게 차세대 항체 치료 시장에 대한 최신 동향에 대한 통찰력을 제공합니다.
- 이 보고서는 다양한 부문/국가에 걸쳐 잠재적인 성장 기회를 파악하고 차세대 항체 치료제 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 보고서 전체에서 차세대 항체 치료제 시장의 새로운 투자 기회, 기존 기업들이 직면한 과제, 지속적인 성장 요인을 파악합니다.
- 차세대 항체 치료제 시장 규모, 예측, CAGR, 코로나19가 시장 역학에 미치는 영향은 조사 범위에서 자세히 논의되며, 포스트 코로나 이후 차세대 항체 치료제 시장에 대한 심층적인 통찰력도 다루고 있습니다.
- 이 보고서는 사용자에게 차세대 항체 치료제 시장에 대한 종합적인 관점을 제공하기 위해 차세대 항체 치료제 시장 경쟁 구도와 주요 혁신가 분석도 포함하고 있습니다.
- 본 조사는 시장 규모, 성장률, 매력도를 기준으로 모든 산업 부문을 벤치마킹한 성장 전망 매핑 분석을 포함합니다.
- 이 보고서는 차세대 항체 치료제 시장에서 활동하는 기업들의 재무 정보와 전략적 이니셔티브를 이해하는 데 도움이 되는 주요 시장 진출기업들에 대한 상세한 기업 프로파일을 제공합니다.
- 또한 이 보고서는 세계뿐만 아니라 지역적 차원에서도 주요 시장 참여자들의 주요 인수합병, 제휴 및 합작투자, 신제품 출시, 연구개발, 지역적 진출에 대한 정보를 제공합니다.
- 차세대 항체 치료 세계 시장 보고서는 주로 공급업체, 투자자, 신규 시장 진출기업, 유통업체, 금융 분석가 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
목차
제1장 차세대 항체 치료 시장 개요
제2장 주요 요약
제3장 차세대 항체 치료 주요 시장 동향
- 차세대 항체 치료 시장 성장 촉진요인
- 차세대 항체 치료 시장 성장 억제요인
- 차세대 항체 치료 시장 기회
- 차세대 항체 치료 시장 향후 동향
제4장 차세대 항체 치료 산업 조사
- PEST 분석
- Porter의 Five Forces 분석
- 성장 전망 매핑
- 규제 구조 분석
제5장 차세대 항체 치료 시장 : COVID-19의 영향 분석
- 신형 코로나바이러스 이전의 영향 분석
- 신형 코로나바이러스 이후의 영향 분석
제6장 차세대 항체 치료 시장 구도
- 차세대 항체 치료 시장 점유율 분석, 2022년
- 주요 제조업체별 분석 데이터
제7장 차세대 항체 치료 시장 - 치료 분야별
- 개요
- 질환 영역별 부문 점유율 분석
- 종양학
- 자가면역/염증
제8장 차세대 항체 치료 시장 - 기술별
- 개요
- 부문 점유율 분석(기술별)
- 항체 약물 결합체(ADC)
- 이중 특이성 항체
- Fc 조작 항체
- 항체 단편 및 항체 유사 단백질
- 바이오시밀러 항체 제품
제9장 차세대 항체 치료 시장 - 지역별
- 서론
- 북미
- 개요
- 차세대 항체 치료 북미 주요 제조업체
- 미국
- 캐나다
- 유럽
- 개요
- 차세대 항체 치료 유럽 주요 제조업체
- 독일
- 이탈리아
- 영국
- 프랑스
- 러시아
- 네덜란드
- 스웨덴
- 폴란드
- 기타
- 아시아태평양(APAC)
- 개요
- 차세대 항체 치료 아시아태평양 주요 제조업체
- 인도
- 중국
- 일본
- 한국
- 호주
- 태국
- 인도네시아
- 필리핀
- 기타
- 라틴아메리카
- 개요
- 차세대 항체 치료 라틴아메리카 주요 제조업체
- 브라질
- 멕시코
- 아르헨티나
- 콜롬비아
- 기타
- 중동 및 아프리카
- 개요
- 차세대 항체 치료 중동 및 아프리카 주요 제조업체
- 사우디아라비아
- 아랍에미리트(UAE)
- 이스라엘
- 터키
- 알제리
- 이집트
- 기타
제10장 주요 벤더 분석 - 차세대 항체 치료 산업
- 경쟁 대시보드
- 기업 개요
- Pfizer
- Roche
- Bristol-Myers Squibb
- Amgen
- AstraZeneca
- Bayer
- Takeda Pharmaceuticals
- Biogen
- Seattle Genetics
- ImmunoGen
- Kyowa Hakko Kirin
- Xencor
- Dyax CorpC
제11장 애널리스트의 다각적 관점
LSH
REPORT HIGHLIGHT
Next-Generation Antibody Therapeutics Market size was valued at USD 5,007.1 million in 2022, expanding at a CAGR of 10.3% from 2023 to 2030.
The next generation of antibody therapeutics, with engineering to enhance characteristics such as target cell-killing potency. These include antibody-drug conjugates (ADCs), bispecific antibodies, engineered antibodies, antibody fragments, and Nanobodies. Monoclonal antibodies (mAb) are emerging as one of the major class of therapeutic agents in the treatment of many human diseases, in particular in cancer and immunological disorders. To date, 28 mAb have been approved by the United States Food and Drug Administration for clinical applications. In addition, several hundreds of mAb are being developed clinically by many biotech and pharmaceutical companies for various disease indications.
Next-Generation Antibody Therapeutics Market- Market Dynamics
Increase in the prevalence of different chronic diseases such as rheumatoid arthritis, inflammatory bowel disorder, Crohn's disease, and cancer to propel market demand
Next-generation antibody therapeutics hold significant promise in the treatment of chronic diseases. Several chronic diseases have seen a rise in their prevalence in recent years, including cardiovascular diseases, diabetes, cancer, autoimmune disorders, neurodegenerative diseases, and respiratory conditions, among others. According to the world health organization, Cardiovascular diseases (CVDs) are the leading cause of death globally, taking an estimated 17.9 million lives each year. However, Traditional treatment options for chronic diseases include chemotherapy, radiation, immunosuppressive drugs, and long-term use of medications to control symptoms. with continued advancements in the field of biotechnology and the growing understanding of disease mechanisms, next-generation antibody therapeutics have the potential to revolutionize the treatment landscape for various chronic diseases, improving patient results and quality of life.
Next-Generation Antibody Therapeutics Market- Key Insights
- As per the analysis shared by our research analyst, the global Next-Generation Antibody Therapeutics market is estimated to grow annually at a CAGR of around XX% over the forecast period (2023-2030)
- The Next-Generation Antibody Therapeutics industry is projected to grow at a significant rate due to the growing awareness of sustainable growth
- Based on therapeutic area segmentation, Oncology was predicted to show maximum market share in the year 2022
- Based on technology segmentation, Antibody-Drug Conjugates were the leading type in 2022
- On the basis of region, North America was the leading revenue generator in 2022
Next-Generation Antibody Therapeutics Market- Segmentation Analysis:
The Global Next-Generation Antibody Therapeutics Market is segmented on the basis of therapeutic area, Technology, and Region.
The market is divided into three categories based on Therapeutic areas: Oncology and Autoimmune/Inflammatory. Oncology dominates the market and is likely to maintain its dominance during the forecast period. Oncology is one of the key therapeutic areas where next-generation antibody therapeutics have made significant advancements and demonstrated great potential.
The market is divided into three categories based on technology: Antibody-Drug Conjugates (ADCs), Bispecific Antibodies, Fc-engineered Antibodies, Antibody Fragments and Antibody-like Proteins, and Biosimilar Antibody Products. Antibody-Drug Conjugates dominates Next-Generation Antibody Therapeutics Market. Antibody-drug conjugates (ADCs) are a class of next-generation antibody therapeutics that combine the specificity of monoclonal antibodies with the cytotoxic effects of chemotherapy drugs.
Next-Generation Antibody Therapeutics Market- Geographical Insights
Geographically, this market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business. North America is anticipated to dominate the growth of the next-generation antibody therapeutics market, due to the rise in auto-immune diseases, and increased healthcare expenditure. Next-generation antibody therapeutics show significant promise in the treatment of autoimmune diseases by offering targeted and specific interventions. According to the National Institutes of Health, up to 23.5 million Americans suffer from an autoimmune disease and the prevalence is rising. next-generation antibody therapeutics have the potential to address some of these challenges and potentially contribute to more efficient healthcare spending. In 2021, spending was USD187.6 billion, less than the unprecedented levels in 2020, but still higher than before the pandemic. Government-sponsored pandemic relief resulted in other federal programs spending increasing from only USD14.0 billion in 2019 to USD193.1 billion in 2020. In 2021, spending was USD71.9 billion, according to American Medical Association. Overall, Next-Generation Antibody Therapeutics Market is expected to experience significant growth opportunities in all regions.
Next-Generation Antibody Therapeutics Market- Competitive Landscape:
An assembly of novel therapeutic antibody formats based on the modification of the conventional IgG format has arisen in recent years. In addition, several hundreds of Next-Generation Antibody Therapeutics are being developed clinically by many biotech and pharmaceutical companies for various disease indications. Many challenges still remain, however, and the full potential of therapeutic antibodies has yet to be realized. With the advancement of antibody engineering technologies and further understanding of disease biology as well as antibody mechanism of action, many classes of novel antibody formats or antibody-derived molecules are emerging as promising new-generation therapeutics. These new antibody formats or molecules are carefully designed and engineered to acquire special features, such as improved pharmacokinetics, increased selectivity, and enhanced efficacy. Numerous companies and research institutions are actively involved in the development and commercialization of these innovative therapies. For instance, on Jan. 6, 2022, Amgen and Generate Biomedicines nowadays announced a research collaboration agreement to discover and create protein therapeutics for five clinical targets across several therapeutic areas and multiple modalities.
Recent Developments:
In September 2022, the Evolution of monoclonal antibodies resulted in the next generation of antibody therapeutics, with engineering to enhance characteristics such as target cell-killing potency. These include antibody-drug conjugates (ADCs), bispecific antibodies, engineered antibodies, antibody fragments, and Nano bodies.
Key features of the study:
- This proposed research study on Next-Generation Antibody Therapeutics market provides market size (US$ million), compound annual growth rate (CAGR %) and forecast estimation (2023-2030), considering 2022 as the base year
- The report provides the client the latest up-to-date and trending insights about the Next-Generation Antibody Therapeutics market.
- The research report elucidates potential growth opportunities across different segments/countries and explains attractive investment proposition matrix for the Next-Generation Antibody Therapeutics market
- The overall report identifies new investment opportunities, challenges faced by established players, and growth factors to sustain in the Next-Generation Antibody Therapeutics market
- Impact of COVID-19 on Next-Generation Antibody Therapeutics market size, forecast, CAGR, and market dynamics are discussed in detail under the research scope. Detailed insight on Next-Generation Antibody Therapeutics market post-COVID will also be covered.
- In order to give the users of this report a comprehensive view on the Next-Generation Antibody Therapeutics market, we have also included competitive landscape and key innovator analysis for the Next-Generation Antibody Therapeutics market.
- The study encompasses a growth prospect mapping analysis, wherein all the industry segments are benchmarked based on their market size, growth rate and attractiveness.
- The report offers detailed company profiling featuring major market participants which will help users to understand their financial information and strategic initiatives of players operating in the Next-Generation Antibody Therapeutics market.
- In addition, the report also unveil the important acquisitions & mergers, collaborations & joint ventures, new launch, research & development, regional expansion of major participants involved in the market on global as well as regional level.
- The global Next-Generation Antibody Therapeutics market report primarily caters to various stakeholders in this industry including suppliers, investors, new entrants, distributors, and financial analysts
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET KEY PLAYERS
- Pfizer
- Roche
- Bristol-Myers Squibb
- Amgen
- AstraZeneca
- Bayer
- Takeda Pharmaceuticals
- Biogen
- Seattle Genetics
- ImmunoGen
- Kyowa Hakko Kirin
- Xencor
- Dyax CorpC
GLOBAL NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, BY THERAPEUTIC AREA
- Oncology
- Autoimmune/Inflammatory
GLOBAL NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, BY TECHNOLOGY
- Antibody-Drug Conjugates (ADCs)
- Bispecific Antibodies
- Fc-engineered Antibodies
- Antibody Fragments and Antibody-like Proteins
- Biosimilar Antibody Products
GLOBAL NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, BY REGION
- North America
- The U.S.
- Canada
- Europe
- Germany
- France
- Italy
- Spain
- United Kingdom
- Russia
- Netherlands
- Sweden
- Poland
- Rest of Europe
- Asia Pacific
- India
- China
- South Korea
- Japan
- Australia
- Thailand
- Indonesia
- Philippines
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
- The Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA
TABLE OF CONTENT
1. Next-Generation Antibody Therapeutics Market Overview
2. Executive Summary
- 2.1. Market Snippet
- 2.1.1. Next-Generation Antibody Therapeutics Market Snippet by Therapeutic Area
- 2.1.2. Next-Generation Antibody Therapeutics Market Snippet by Technology
- 2.1.3. Next-Generation Antibody Therapeutics Market Snippet by Country
- 2.1.4. Next-Generation Antibody Therapeutics Market Snippet by Region
- 2.2. Competitive Insights
3. Next-Generation Antibody Therapeutics Key Market Trends
- 3.1. Next-Generation Antibody Therapeutics Market Drivers
- 3.1.1. Impact Analysis of Market Drivers
- 3.2. Next-Generation Antibody Therapeutics Market Restraints
- 3.2.1. Impact Analysis of Market Restraints
- 3.3. Next-Generation Antibody Therapeutics Market Opportunities
- 3.4. Next-Generation Antibody Therapeutics Market Future Trends
4. Next-Generation Antibody Therapeutics Industry Study
- 4.1. PEST Analysis
- 4.2. Porter's Five Forces Analysis
- 4.3. Growth Prospect Mapping
- 4.4. Regulatory Framework Analysis
5. Next-Generation Antibody Therapeutics Market: COVID-19 Impact Analysis
- 5.1. Pre-COVID-19 Impact Analysis
- 5.2. Post-COVID-19 Impact Analysis
- 5.2.1. Top Performing Segments
- 5.2.2. Marginal Growth Segments
- 5.2.3. Top Looser Segments
- 5.2.4. Marginal Loss Segments
6. Next-Generation Antibody Therapeutics Market Landscape
- 6.1. Next-Generation Antibody Therapeutics Market Share Analysis, 2022
- 6.2. Breakdown Data, by Key Manufacturer
- 6.2.1. Established Players' Analysis
- 6.2.2. Emerging Players' Analysis
7. Next-Generation Antibody Therapeutics Market - By Therapeutic Area
- 7.1. Overview
- 7.1.1. Segment Share Analysis, By Therapeutic Area, 2022 & 2030 (%)
- 7.1.2. Oncology
- 7.1.3. Autoimmune/Inflammatory
8. Next-Generation Antibody Therapeutics Market - By Technology
- 8.1. Overview
- 8.1.1. Segment Share Analysis, By Technology, 2022 & 2030 (%)
- 8.1.2. Antibody-Drug Conjugates (ADCs)
- 8.1.3. Bispecific Antibodies
- 8.1.4. Fc-engineered Antibodies
- 8.1.5. Antibody Fragments and Antibody-like Proteins
- 8.1.6. Biosimilar Antibody Products
9. Next-Generation Antibody Therapeutics Market- By Geography
- 9.1. Introduction
- 9.1.1. Segment Share Analysis, By Geography, 2022 & 2030 (%)
- 9.2. North America
- 9.2.1. Overview
- 9.2.2. Next-Generation Antibody Therapeutics Key Manufacturers in North America
- 9.2.3. North America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
- 9.2.4. North America Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
- 9.2.5. North America Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
- 9.2.6. U.S.
- 9.2.6.1. Overview
- 9.2.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 9.2.6.3. U.S. Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
- 9.2.6.4. U.S. Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
- 9.2.7. Canada
- 9.2.7.1. Overview
- 9.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 9.2.7.3. Canada Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
- 9.2.7.4. Canada Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
- 9.3. Europe
- 9.3.1. Overview
- 9.3.2. Next-Generation Antibody Therapeutics Key Manufacturers in Europe
- 9.3.3. Europe Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
- 9.3.4. Europe Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
- 9.3.5. Europe Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
- 9.3.6. Germany
- 9.3.6.1. Overview
- 9.3.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 9.3.6.3. Germany Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
- 9.3.6.4. Germany Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
- 9.3.7. Italy
- 9.3.7.1. Overview
- 9.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 9.3.7.3. Italy Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
- 9.3.7.4. Italy Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
- 9.3.8. United Kingdom
- 9.3.8.1. Overview
- 9.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 9.3.8.3. United Kingdom Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
- 9.3.8.4. United Kingdom Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
- 9.3.9. France
- 9.3.9.1. Overview
- 9.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 9.3.9.3. France Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
- 9.3.9.4. France Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
- 9.3.10. Russia
- 9.3.10.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 9.3.10.2. Russia Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
- 9.3.10.3. Russia Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
- 9.3.11. Netherlands
- 9.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 9.3.11.2. Netherlands Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
- 9.3.11.3. Netherlands Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
- 9.3.12. Sweden
- 9.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 9.3.12.2. Sweden Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
- 9.3.12.3. Sweden Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
- 9.3.13. Poland
- 9.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 9.3.13.2. Poland Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
- 9.3.13.3. Poland Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
- 9.3.14. Rest of Europe
- 9.3.14.1. Overview
- 9.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 9.3.14.3. Rest of the Europe Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
- 9.3.14.4. Rest of the Europe Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
- 9.4. Asia Pacific (APAC)
- 9.4.1. Overview
- 9.4.2. Next-Generation Antibody Therapeutics Key Manufacturers in Asia Pacific
- 9.4.3. Asia Pacific Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
- 9.4.4. Asia Pacific Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
- 9.4.5. Asia Pacific Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
- 9.4.6. India
- 9.4.6.1. Overview
- 9.4.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 9.4.6.3. India Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
- 9.4.6.4. India Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
- 9.4.7. China
- 9.4.7.1. Overview
- 9.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 9.4.7.3. China Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
- 9.4.7.4. China Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
- 9.4.8. Japan
- 9.4.8.1. Overview
- 9.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 9.4.8.3. Japan Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
- 9.4.8.4. Japan Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
- 9.4.9. South Korea
- 9.4.9.1. Overview
- 9.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 9.4.9.3. South Korea Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
- 9.4.9.4. South Korea Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
- 9.4.10. Australia
- 9.4.10.1. Overview
- 9.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 9.4.10.3. Australia Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
- 9.4.10.4. Australia Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
- 9.4.11. Thailand
- 9.4.11.1. Overview
- 9.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 9.4.11.3. Thailand Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
- 9.4.11.4. Thailand Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
- 9.4.12. Indonesia
- 9.4.12.1. Overview
- 9.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 9.4.12.3. Indonesia Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
- 9.4.12.4. Indonesia Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
- 9.4.13. Philippines
- 9.4.13.1. Overview
- 9.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 9.4.13.3. Philippines Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
- 9.4.13.4. Philippines Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
- 9.4.14. Rest of APAC
- 9.4.14.1. Overview
- 9.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 9.4.14.3. Rest of APAC Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
- 9.4.14.4. Rest of APAC Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
- 9.5. Latin America
- 9.5.1. Overview
- 9.5.2. Next-Generation Antibody Therapeutics Key Manufacturers in Latin America
- 9.5.3. Latin America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
- 9.5.4. Latin America Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
- 9.5.5. Latin America Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
- 9.5.6. Brazil
- 9.5.6.1. Overview
- 9.5.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 9.5.6.3. Brazil Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
- 9.5.6.4. Brazil Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
- 9.5.7. Mexico
- 9.5.7.1. Overview
- 9.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 9.5.7.3. Mexico Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
- 9.5.7.4. Mexico Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
- 9.5.8. Argentina
- 9.5.8.1. Overview
- 9.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 9.5.8.3. Argentina Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
- 9.5.8.4. Argentina Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
- 9.5.9. Colombia
- 9.5.9.1. Overview
- 9.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 9.5.9.3. Colombia Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
- 9.5.9.4. Colombia Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
- 9.5.10. Rest of LATAM
- 9.5.10.1. Overview
- 9.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 9.5.10.3. Rest of LATAM Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
- 9.5.10.4. Rest of LATAM Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
- 9.6. Middle East and Africa
- 9.6.1. Overview
- 9.6.2. Next-Generation Antibody Therapeutics Key Manufacturers in Middle East and Africa
- 9.6.3. Middle East and Africa Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
- 9.6.4. Middle East and Africa Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
- 9.6.5. Middle East and Africa Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
- 9.6.6. Saudi Arabia
- 9.6.6.1. Overview
- 9.6.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 9.6.6.3. Saudi Arabia Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
- 9.6.6.4. Saudi Arabia Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
- 9.6.7. United Arab Emirates
- 9.6.7.1. Overview
- 9.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 9.6.7.3. United Arab Emirates Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
- 9.6.7.4. United Arab Emirates Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
- 9.6.8. Israel
- 9.6.8.1. Overview
- 9.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 9.6.8.3. Israel Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
- 9.6.8.4. Israel Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
- 9.6.9. Turkey
- 9.6.9.1. Overview
- 9.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 9.6.9.3. Turkey Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
- 9.6.9.4. Turkey Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
- 9.6.10. Algeria
- 9.6.10.1. Overview
- 9.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 9.6.10.3. Algeria Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
- 9.6.10.4. Algeria Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
- 9.6.11. Egypt
- 9.6.11.1. Overview
- 9.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 9.6.11.3. Egypt Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
- 9.6.11.4. Egypt Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
- 9.6.12. Rest of MEA
- 9.6.12.1. Overview
- 9.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 9.6.12.3. Rest of MEA Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
- 9.6.12.4. Rest of MEA Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
10. Key Vendor Analysis- Next-Generation Antibody Therapeutics Industry
- 10.1. Competitive Dashboard
- 10.2. Company Profiles
- 10.2.1. Pfizer
- 10.2.2. Roche
- 10.2.3. Bristol-Myers Squibb
- 10.2.4. Amgen
- 10.2.5. AstraZeneca
- 10.2.6. Bayer
- 10.2.7. Takeda Pharmaceuticals
- 10.2.8. Biogen
- 10.2.9. Seattle Genetics
- 10.2.10. ImmunoGen
- 10.2.11. Kyowa Hakko Kirin
- 10.2.12. Xencor
- 10.2.13. Dyax CorpC
11. 360 Degree Analyst View
12. Appendix
- 12.1. Research Methodology
- 12.2. References
- 12.3. Abbreviations
- 12.4. Disclaimer
- 12.5. Contact Us
